Stockreport

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

AtaiBeckley Inc.  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clin [Read more]